

SWANSON & BRATSCHUN, L.L.C.

DENVER TECHNOLOGICAL CENTER  
8400 EAST PRENTICE AVENUE  
SUITE 200  
ENGLEWOOD, COLORADO 80111  
TELEPHONE (303) 793-3333  
FACSIMILE (303) 793-3433

PATENTS, COPYRIGHTS  
AND TRADEMARKS

November 7, 1994


Theresa A. Brown  
Synergen, Inc.  
1885 33rd Street  
Boulder, CO 80301

Re: U.S. Application Serial No. 08/182,183  
Glial Derived Neurotrophic Factor  
Our Ref: SYN225/C4-US

Dear Theresa:

I have enclosed a copy of the Corrected Filing Receipt for your files.

Very truly yours,



Rosemary P. Kellogg

RPK:tec  
Enclosure  
synergen\225\brown-us.01 /tec

FILING RECEIPT


CORRECTED



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
08/182,183	05/23/94	1812	\$2,846.00	SYNE225/C4-U	30	74	15

SWANSON & BRATSCUN L L C  
SUITE 200  
8400 E PRENTICE AVENUE  
ENGLEWOOD CO 80111



Receipt is acknowledged of this patent application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

LEU-FEN H. LIN, BOULDER, CO; FRANKLIN D. COLLINS,  
AGOURA HILLS, CA; DANIEL H. DOHERTY, BOULDER, CO; JACK  
LILE, NEDERLAND, CO; SUSAN BEKTESH, BOULDER, CO.

CONTINUING DATA AS CLAIMED BY APPLICANT-

THIS APPLN IS A 371 OF PCT/US92/07888 09/17/92

FOREIGN/PCT APPLICATIONS-PCT

PCT/US92/07888 09/17/92

FOREIGN FILING LICENSE GRANTED 08/01/94

TITLE

GLIAL DERIVED NEUROTROPHIC FACTOR

PRELIMINARY CLASS: 530

**LICENSE FOR FOREIGN FILING UNDER**

**Title 35, United States Code, Section 184**

**Title 37, Code of Federal Regulations, 5.11**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). This license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license has been granted under 37 CFR 5.13.

This license is to be retained by the licensee and may be used at anytime on or after the effective date thereof unless it is revoked. This license is transferrable to any related application(s) filed under 37 CFR 1.62 which meet the provisions of 37 CFR 5.15(a)(4). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR, Parts 121-128) ); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j) ); and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "FOREIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12 (b), if a license is desired.